Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss			$ (7,638,987)	$ (106,195,167)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development				72,523,293
Depreciation and amortization			634	6,666
Stockbased compensation			285,567	16,885,675
Amortization of right of use lease asset				120,795
Foreign currency gain	$ (56,363)	$ (154,566)	(42,566)	(290,777)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			410,246	2,126,847
Accounts payable			289,605	2,288,527
Accrued expenses and other liabilities			499,516	(1,756,495)
Lease liability				(107,306)
Net cash used in operating activities			(6,195,985)	(14,397,942)
Cash flows from financing activities:
Proceeds from issuance of common stock			5,788,918
Common stock issuance costs			(648,928)
Net cash provided by financing activities			5,139,990
Change in cash and cash equivalents			(1,055,995)	(14,397,942)
Effect of exchange rate changes on cash			(5,341)	384,305
Cash and cash equivalents-beginning of year			28,786,647	53,076,052
Cash and cash equivalents-end of period	27,725,311	39,062,415	27,725,311	39,062,415
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	27,685,131	39,062,415	27,685,131	39,062,415
Restricted cash	40,180		40,180
Total cash, cash equivalents and restricted cash	$ 27,725,311	$ 39,062,415	$ 27,725,311	39,062,415
Non-cash investing and financing activities:
Operating lease liabilities arising from obtaining right-of-use assets				123,786
Issuance of convertible preferred stock and common stock in connection with acquisition				$ 70,107,167